Facebook
Twitter
LinkedIn
ForwardMayo Clinic Cardio-Oncology Update 2025
Overview
This course offers Live (in-person) and Livestream (virtual) attendance options
Course Directors : Chadi Ayoub, M.B.B.S., Ph.D., Joerg Herrmann, M.D., Carolyn M. Larsen, M.D., Lida A. Mina, M.D. and Chris Ray, M.D.
November 6 - 9, 2025 - Conrad Orlando - Orlando, Florida
2025 will be the seventh Mayo Cardio-Oncology course. Each year, the course directors have improved the educational content in response to feedback from attendees and speakers to try to better meet the needs of the audience and the cardio-oncology community. The goal remains to host a course that will be educational for both those active in clinical practice and research in cardio-oncology, as well as for those hoping to expand their practice into the field of cardio-oncology. Additionally, this course aims to broaden the scope to appeal to a diverse audience as cardio-oncology is a specialty that requires multidisciplinary collaboration for optimal patient care. This course reviews the prevention, diagnosis, and management of cardiac and vascular diseases of cancer patients throughout the continuum of their care including heart failure, myocardial ischemia, hypertension, thromboembolism, and arrhythmia. The course is directed towards the spectrum of providers who care for cancer patients to enable them to recognize the cardiovascular risk of their patients and take action to minimize this risk. This includes physicians, advance practice providers, pharmacists, and nurses in cardiology, hematology-oncology, primary care, and hospital internal medicine. The course will include lectures from experts as well as interactive case-based and question and answer sessions.
| Registration - Live (in-person) | On or Before October 6 | After October 6 |
|---|---|---|
| M.D., D.O., Ph.D. | $950 | $1025 |
| Allied Health, NP, PA, Retirees | $850 | $925 |
| Registration - Livestream (virtual) | $950 | $850 |
| IC-OS Board Review | $150 | $150 |
IC-OS Board Review Sessions. During the optional sessions, IC-OS members will review board style questions with participants. Participation in all board review sessions will offer 3.00 additional credit hours and requires separate registration. The target audience is attendees who are considering registering for the IC-OS Cardio-Oncology Board Certification Exam (https://ic-os.org/board-certification-admin/) or any attendees who are interested in additional cardio-oncology education in a question and answer format.
The objectives of the board review sessions are to:
- Solidify knowledge gained throughout the course by reviewing board style questions and answers with cardio-oncology experts
- Help prepare participants for the IC-OS Cardio-Oncology Board Certification certificate exam
Target Audience
This course is designed for general cardiologists, heart failure specialists, and advanced practice providers working in cardiology who either currently practice cardio-oncology or aim to expand their practice into the field to optimize the care of this patient population. The course is also designed for providers in hematology, oncology, and internal medicine as they are often the first to encounter and diagnose patients with cardiotoxicity related to cancer therapies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Develop an approach to the prevention of cancer therapeutics related cardiotoxicity.
- Develop an approach to the management of cancer therapeutics related cardiotoxicity.
- Summarize guideline based cardiovascular surveillance during cancer therapy associated with a risk of cardiovascular toxicity.
- Identify an approach to the integration of multimodality imaging into the cardio-oncology practice.
- Review advances in the management of TTR and AL cardiac amyloidosis.
- Identify key diagnostic modalities for early detection of cardiac toxicity in cancer patients.
- Review current therapeutic interventions for carcinoid valvular heart disease.
- Assess the cardiovascular risk profile of individuals diagnosed with prostate cancer.
- Recognize unique risk factors for hypertension in cancer patients, including treatment-related factors and comorbidities.
Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.
Program
Cardio-Oncology Update 2025 Program for Web 3-7-2025.pdf
Mayo Clinic Cardio-Oncology Update 2025 | ||
Orlando, Florida | ||
November 6 - 9, 2025 | ||
Time Zone | ||
Day 1 | Thursday, November 6, 2025 | |
11:15 AM | 12:15 PM | Registration, Lunch and Exhibits |
12:15 PM | 12:30 PM | Welcome Announcements |
12:30 PM | 12:55 PM | Intro to Cardio-Oncology: Cancer Therapies |
12:55 PM | 1:20 PM | Intro to Cardio-Oncology: Guideline Based Surveillance Strategy for Chemotherapy Related Cardiotoxicity |
1:20 PM | 1:45 PM | Intro to Cardio-Oncology: Prevention and Management of Chemotherapy Related Cardiotoxicity |
1:45 PM | 2:10 PM | Q&A |
2:10 PM | 2:25 PM | Exhibits and Break |
2:25 PM | 2:50 PM | Targeted Therapies for Breast Cancer |
2:50 PM | 3:15 PM | Advanced Heart Failure Management in Cardio-Oncology |
3:15 PM | 3:40 PM | Role of Advanced Imaging in Cardio-Oncology |
3:40 PM | 4:05 PM | Artificial Intelligence in Cardio-Oncology: The Future of Risk Stratification and Early Detection. |
4:05 PM | 4:30 PM | Question and Answer Session |
4:30 PM | 4:45 PM | Break |
4:45 PM | 5:45 PM | IC-OS Session |
5:45 PM | 5:45 PM | Adjourn |
Day 2 | Friday, November 7, 2025 | |
7:00 AM | 7:55 AM | Registration, Breakfast and Exhibits |
7:55 AM | 8:00 AM | Announcements |
8:00 AM | 8:25 AM | Updates in Cardio-Oncology 2025: Current state of cardio-oncology practice and where do we go from here? |
8:25 AM | 8:50 AM | Challenging case(s) in the management of Checkpoint Inhibitor Cardiotoxicity |
8:50 AM | 9:15 AM | Challenging case(s) in the cardiac management of patients undergoing CAR-T therapy: Case presentation and table disucssion |
9:15 AM | 9:40 AM | Pericardial effusion and Pericarditis Case(s) |
9:40 AM | 10:05 AM | Question and Answer Session |
10:05 AM | 10:20 AM | Exhibits and Break |
10:20 AM | 10:45 AM | Top publications in Cardio-Oncology 2025 |
10:45 AM | 11:10 AM | Tyroisine Kinase Inhibitor Overview |
11:10 AM | 11:35 AM | BCR-ABL TKI cardiotoxicity case(s) |
11:35 AM | 12:00 PM | Special Considerations in the Management of ACS in Cancer Patients |
12:00 PM | 12:25 PM | Question and Answer Session |
12:25 PM | 12:40 PM | Break |
12:40 PM | 1:40 PM | IC-OS Lunch Session |
Day 3 | Saturday, November 8, 2025 | |
7:00 AM | 7:55 AM | Registration, Breakfast and Exhibits |
7:55 AM | 8:00 AM | Announcements |
8:00 AM | 8:25 AM | Track 1: General Session: My experience building a cardio-oncology practice / Track 2: Specialized Sessions for Advanced Practice Provider: Key pearls from building my cardio-oncology practice: an APP perspective |
8:25 AM | 8:50 AM | Track 1: General Session: Cardio-oncology education / Track 2: Specialized Sessions for Advanced Practice Provider: Introduction to clinical trials research: what you need to know for clinical practice in cardio-oncology |
8:50 AM | 9:15 AM | Track 1: General Session: Cardio-vascular considerations in cancer survivorship / Track 2: Specialized Sessions for Advanced Practice Provider: Challenging Cases of Hypertension Management in Cancer patients |
9:15 AM | 9:40 AM | Track 1: General Session:Exercise and Cardiac Rehab for Cancer Patients and Survivors / Track 2: Specialized Sessions for Advanced Practice Provider: Challenging Inpatient Cardio-oncology case(s) |
9:40 AM | 10:05 AM | Track 1: General Session: Question and Answer Session / Track 2: Specialized Sessions for Advanced Practice Provider: Q&A |
10:05 AM | 10:20 AM | Exhibits and Break |
10:20 AM | 10:45 AM | Stem Cell Transplant and the Heart |
10:45 AM | 11:10 AM | CHIP |
11:10 AM | 11:35 AM | Prostate Cancer and Heart Disease |
11:35 AM | 12:00 PM | Hormone Therapy and Cardiac Risk in Breast Cancer |
12:00 PM | 12:25 PM | Question and Answer Session |
12:25 PM | 12:40 PM | Break |
12:40 PM | 1:40 PM | IC-OS Lunch Session |
Day 4 | Sunday, November 9, 2025 | |
7:00 AM | 7:55 AM | Registration, Breakfast and Exhibits |
7:55 AM | 8:00 AM | Announcements |
8:00 AM | 8:25 AM | Malignant Cardiac Mass Case(s) |
8:25 AM | 8:50 AM | Radiation Heart Disease Case(s) |
8:50 AM | 9:15 AM | Radiation Induced Vasculopathy |
9:15 AM | 9:40 AM | My approach to the diagnosis and management of carcinoid syndrome |
9:40 AM | 10:05 AM | Carcinoid Heart Disease Case(s) |
10:05 AM | 10:20 AM | Question and Answer Session |
10:20 AM | 10:45 AM | Exhibits and Break |
10:45 AM | 11:10 AM | Novel Therapies for TTR Cardiac Amyloid |
11:10 AM | 11:35 AM | Treatment of AL amyloid with cardiac involvement |
11:35 AM | 12:00 PM | Atrial fibrillation management in Cardiac Amyloid |
12:00 PM | 12:25 PM | Question and Answer Session |
12:25 PM | 12:25 PM | Adjourn |
Location
Notify me when Mayo Clinic Cardio-Oncology Update 2025 hotel information is available.
All travel and lodging expenses are the sole responsibility of the individual registrant.
Faculty
Course Directors
Chadi Ayoub, M.B.B.S., Ph.D.
Joerg Herrmann, M.D.
Carolyn M. Larsen, M.D.
Lida A. Mina, M.D.
Chris Ray, M.D.
Guest Faculty
Daniel Lenihan, MD, FACC, FESC, FIC-OS
Accreditation
Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Statement(s):
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 19.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE
Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 19.00 ACPE Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity.
UAN Number: TBD
ANCC
Mayo Clinic College of Medicine and Science designates this activity for a maximum of 19.00 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professionals:
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
Available Credit
- 19.00 ACPE
- 19.00 AMA PRA Category 1 Credit™
- 19.00 ANCC
- 19.00 Attendance
Register
Please update your profile to let us know if you have dietary restrictions or access requirements.
To claim credit for livestream participation in this course, learners must view the content during the hours posted for the live activity. This course is not approved for on-demand delivery.
Commitment to Equity, Diversity and Inclusion
Mayo Clinic School of Continuous Professional Development (MCSCPD) strives to foster a learning environment in which individual differences are valued, allowing all to achieve their fullest potential.
Cancellation and Refund Policy
View Cancellation and Refund Policy
All requests must be submitted in writing using the Contact Us Form.
Any use of this site constitutes your agreement to the Terms and Conditions of Registration.